Cell-Free Technology established at Insempra

Cell-Free Technology established at Insempra

28.11.2022 · 4 min. read

, Linkedin, Twitter

by Sung-Hui Yi, Scientist Protein Biochemistry & Luisa Gronenberg, Head of R&D for Functional Ingredients & Strain Engineering

Scent, flavor, color, and other properties are what make our favorite food and personal care products particularly special. Increasingly, these ingredients come from exploitative processes. At Insempra we build microbial strains that can convert renewable feedstocks to natural ingredients by precision fermentation – a natural process that is non-exploitative.

To make the most efficient microbes for producing our natural ingredients we have to screen through thousands of metabolic designs. Building each of these designed microbial strains is one of the most time-intensive steps in our development process. Therefore, at Insempra, we have built a cell-free platform to test metabolic designs quickly and accelerate time to market.

We have set up our cell-free system as a fast-screening platform together with our scientific advisor Prof. Michael Jewett from Northwestern University. Jewett is a pioneer in the area of cell-free metabolic engineering, building metabolic pathways in cell lysate as a way to directly access and control the many “knobs” of metabolism such as protein variants, protein levels and concentration of cofactors. In recent years, his group has applied cell-free systems to the synthesis of numerous sustainable bioproducts, like styrene (Grubbe, Metabolic Engineering, 2020), butanol (Karim, Nature Chemical Biology, 2020), limonene (Dudley, Metabolic Engineering, 2021), acetone (Liew, Nature Biotechnology, 2022), and hexanol (Vogeli, Nature Communications, 2022).

One of the major ways we apply the cell-free systems is by Cell-Free Protein Synthesis (CFPS). In CFPS, the transcription and translation machinery are reconstructed in cell-free reactions. By introducing DNA bearing one or multiple genes of interest, we are able to synthesize target proteins within a few hours and characterize their functions immediately. As shown in Figure 1 this eliminates the time-consuming steps in conventional strain construction of cloning of a gene into a plasmid, transformation of the plasmid into a microbial cell, culturing and harvesting the cells (and potentially purifying the protein) before assaying the protein function. This allows us to compare the efficiency of single or combinations of enzymes and narrows down the number of designs before we construct complex pathways in cells. Our cell-free process decreases the time required to achieve desired process objectives.

Figure 1: Comparison of conventional and cell-free strain engineering workflows.

(A) In conventional strain engineering combinations of genes are cloned into plasmids with regulatory elements such as promoters, ribosome binding sites and terminators. Assembling and verifying the plasmids, transformation of the plasmids into expression strains (shown here as yeast cells) and cultivating and assaying the strains takes days to weeks. 
(B) With a cell-free strain design system, DNA bearing the target genes can be directly added to the cell-free reaction mixture in different combinations. This can be done in a very high throughput setup. Proteins are synthesized in the cell-free reaction and the metabolic pathway can be directly assayed. This allows the identification of promising designs within one working day. 

Sources: 

Vogeli B, Schulz L, Garg S, Tarasava K, Clomburg JM, Lee SH, Gonnot A, Moully EH, Kimmel BR, Mrksich M, Karim AS, Gonzalez R, Kopke M, Jewett MC. (2022) “Cell-free prototyping enables implementation of optimized reverse b-oxidation pathways in heterotrophic and autotrophic bacteria” Nature Communications, 13: 3058

Grubbe WS, Rasor BJ, Krüger A, Jewett MC, Karim AS (2020) “Cell-free styrene biosynthesis at high titers” Metabolic Engineering 61: 89-95

Dudley QM, Karim AS, Nash CJ, Jewett MC (2020) “In vitro prototyping of limonene biosynthesis using cell-free protein synthesis” Metabolic Engineering 61: 251-260

Liew, F.,† Nogle, R.,† Abdalla, T.,† Rasor, B.J., Canter, C., Jensen,R.O., Wang, L., Strutz, J., Chirania, P., Tissera, S.D., Mueller, A.P., Ruan, Z., Gao, A., Tran, L., Bromley, J.C., Daniell, J., Conrado, R., Tschaplinski, T.J., Giannone, R.J., Hettich, R.L., Karim, A.S., Simpson, S.D., Brown, S.D., Leang, C.,* Jewett, M.C.,* and Köpke, M.* 2022. Carbon-negative production of acetone and isopropanol by gas fermentation at industrial pilot scale.

Karim, A.S., Dudley, Q.M., Juminaga, A., Yuan, Y., Crowe, S.A., Heggestad, J.T.,  Garg, S., Abdalla, T., Grubbe, W.,% Rasor, B., Coar, D., Torculas, M., Krein, M., Liew, F., Quattlebaum, A., Jensen, R.O., Stuart, J., Simpson, S.D., Köpke, M., and Jewett, M.C.* 2020. In vitro prototyping and rapid optimization of biosynthetic enzymes for cellular design. Nature Chemical Biology. 16: 912-919.

Photo by Louis Reed on Unsplash

Posted by Nicole Laurence

Latest news

Insempra Advances to Stage 2 of the SPRIND Biomanufacturing Challenge with a €2m project budget for ‘BioTreasure’ 

We are proud to announce that Insempra has been elected for €1.5 million in funding from The Federal Agency for Disruptive Innovation, SPRIND, in their 2023 circular biomanufacturing challenge for its innovative biomanufacturing prototype, ‘BioTreasure’.

Insempra completes $20 million financing to advance the development of next-generation bio-based ingredients.

Series A investment round will accelerate Insempra’s market-first approach to developing superior, intrinsically sustainable ingredients for the beauty & food industries.

Insempra awarded Eurostars grant to develop fermentative biomelanin with a consortium of innovative European partners. 

Insempra has been awarded a substantial Eurostars grant as a consortium comprising one academic and three industrial partners across three European countries. The consortium was highly recognized and ranked second out of all accepted 216 total, grant-winning European consortiums and was awarded a total funding amount of €2,1M. 

Meet Ed van der Ent, Head of Process Design and Manufacturing

Meet Ed van der Ent, Head of Process Design and Manufacturing

Insempra wins €1.5M disruptive innovation grant with circular biomanufacturing concept ‘BioTreasure’.

We are proud to announce that Insempra has been elected for €1.5 million in funding from The Federal Agency for Disruptive Innovation, SPRIND, in their 2023 circular biomanufacturing challenge for its innovative biomanufacturing prototype, ‘BioTreasure’.

Shaping the future of sustainable flavors and fragrances

We sat down with Ron Honing, CEO of Axxence, to talk about all things flavors and fragrances, the role of biotechnology and how this dynamic market is evolving.  
Insempra and Fibers365 announce successful testing of second-generation feedstock to manufacture fermentation-based products

Insempra and Fibers365 announce successful testing of second-generation feedstock to manufacture fermentation-based products

Insempra and Fibers365 announce successful testing of second-generation feedstock to manufacture fermentation-based products.

Meet Ruchita Chawla, Head of Project Management

Meet Ruchita Chawla, Head of Project Management

Insempra announces first fermentation-based functional ingredient for consumer goods

Insempra has launched its first functional ingredient, a biotechnologically produced, 100% natural alpha-Ionone flavour and fragrance ingredient for food and beauty market applications.

Meet Niharika Singh, Senior Engineering Associate

Meet Niharika Singh, Senior Engineering Associate

Nature grows
— and so does our community.

Read more